Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Free Cash Flow: 2022-2024

Historic Free Cash Flow for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to $6,107.1 billion.

  • Addex Therapeutics' Free Cash Flow fell 26.49% to $6,107.1 billion in Q4 2024 from the same period last year, while for Dec 2024 it was -$67.9 billion, marking a year-over-year decrease of 201.52%. This contributed to the annual value of -$6.1 million for FY2024, which is 31.40% up from last year.
  • Per Addex Therapeutics' latest filing, its Free Cash Flow stood at $6,107.1 billion for Q4 2024, which was up 198.90% from -$6,175.0 billion recorded in Q3 2024.
  • Addex Therapeutics' 5-year Free Cash Flow high stood at $8,307.9 billion for Q4 2023, and its period low was -$6,175.0 billion during Q3 2024.
  • In the last 3 years, Addex Therapeutics' Free Cash Flow had a median value of -$3.4 million in 2022 and averaged -$85.9 million.
  • Over the last 5 years, Addex Therapeutics' Free Cash Flow had its largest YoY gain of 260,550,017.06% in 2023, and its largest YoY loss of 94,015,817.11% in 2023.
  • Over the past 3 years, Addex Therapeutics' Free Cash Flow (Quarterly) stood at -$3.2 million in 2022, then soared by 260,550,017.06% to $8,307.9 billion in 2023, then dropped by 26.49% to $6,107.1 billion in 2024.
  • Its Free Cash Flow stands at $6,107.1 billion for Q4 2024, versus -$6,175.0 billion for Q3 2024 and -$3.6 million for Q2 2024.